Ausgabe 3/2013
Inhalt (23 Artikel)
Clinical pharmacology profile of vorinostat, a histone deacetylase inhibitor
Marian Iwamoto, Evan J. Friedman, Punam Sandhu, Nancy G. B. Agrawal, Eric H. Rubin, John A. Wagner
Compatibility of intravenous fosaprepitant with intravenous 5-HT3 antagonists and corticosteroids
Susan Sun, Joseph Schaller, Jiri Placek, Brett Duersch
Can taxanes provide benefit in patients with CNS tumors and in pediatric patients with tumors? An update on the preclinical development of cabazitaxel
D. Sémiond, S. S. Sidhu, M.-C. Bissery, P. Vrignaud
Clinical effects of A4889G and T6235C polymorphisms in cytochrome P-450 CYP1A1 for breast cancer patients treated with tamoxifen: implications for tumor aggressiveness and patient survival
Cassio Cardoso-Filho, Luis Otavio Sarian, Camila Borges Martins de Oliveira, Leonardo da Silveira Bossi, Gustavo Jacob Lourenço, Carmen Silvia Passos Lima, Maria Salete Costa Gurgel
A phase 2 study of intravenous panobinostat in patients with castration-resistant prostate cancer
Dana E. Rathkopf, Joel Picus, Arif Hussain, Susan Ellard, Kim Nguyen Chi, Thomas Nydam, Erin Allen-Freda, Kaushal Kishor Mishra, Maria Grazia Porro, Howard I. Scher, George Wilding
A phase II study of intra-arterial cisplatin with concurrent radiation and erlotinib for locally advanced head and neck cancer
Krishna Rao, Sini Kalapurakal, Pratima Chalasani, Kathy Robinson, James Malone, Cathy Clausen, Ohad Ronen, Muthuswamy Dhiwakar, Bruce Shevlin, K. Thomas Robbins
Pharmacodynamic modeling of cell cycle and apoptotic effects of gemcitabine on pancreatic adenocarcinoma cells
Salaheldin S. Hamed, Robert M. Straubinger, William J. Jusko
Chemotherapy-induced amenorrhea, menopause-specific quality of life, and endocrine profiles in premenopausal women with breast cancer who received adjuvant anthracycline-based chemotherapy: a prospective cohort study
Changhoon Yoo, Mi Ra Yun, Jin-Hee Ahn, Kyung Hae Jung, Hwa Jung Kim, Jeong Eun Kim, Jeong Yun Park, Kwang Ok Park, Dok Hyun Yoon, Sung-Bae Kim
Phase I and pharmacokinetic/pharmacodynamic study of RO5126766, a first-in-class dual Raf/MEK inhibitor, in Japanese patients with advanced solid tumors
Kazunori Honda, Noboru Yamamoto, Hiroshi Nokihara, Yosuke Tamura, Hajime Asahina, Yasuhide Yamada, Shigenobu Suzuki, Naoya Yamazaki, Yoshitaka Ogita, Tomohide Tamura
Scheduling of paclitaxel and gefitinib to inhibit repopulation for optimal treatment of human cancer cells and xenografts that overexpress the epidermal growth factor receptor
Andrea S. Fung, Man Yu, Qian Jess Ye, Ian F. Tannock
The membrane transport and polyglutamation of pralatrexate: a new-generation dihydrofolate reductase inhibitor
Michele Visentin, Ersin Selcuk Unal, Rongbao Zhao, I. David Goldman
A pilot pharmacologic biomarker study in HLA-haploidentical hematopoietic cell transplant recipients
Meagan J. Bemer, Mohamed Sorror, Brenda M. Sandmaier, Paul V. O’Donnell, Jeannine S. McCune
Phase I, dose-escalation study of AZD7762 alone and in combination with gemcitabine in Japanese patients with advanced solid tumours
Takashi Seto, Taito Esaki, Fumihiko Hirai, Shuji Arita, Kaname Nosaki, Akitaka Makiyama, Takuro Kometani, Chinatsu Fujimoto, Motoharu Hamatake, Hiroaki Takeoka, Felix Agbo, Xiaojin Shi
CPT-11 as a second-line treatment for patients with advanced/metastatic gastric cancer who failed S-1 (CCOG0702)
Yoshinari Mochizuki, Norifumi Ohashi, Hiroshi Kojima, Kiyoshi Ishigure, Takashi Kinoshita, Takehiko Eguchi, Shinichi Fujitake, Seiji Ito, Michitaka Fujiwara, Yasuhiro Kodera
A randomized controlled trial of gemcitabine plus cisplatin versus gemcitabine alone in the treatment of metastatic pancreatic cancer
Yee Chao, Chen-Yi Wu, Jack P. Wang, Rheun-Chuan Lee, Wei-Ping Lee, Chung-Pin Li
Phase 1 pharmacokinetic study of MK-0646 (dalotuzumab), an anti-insulin-like growth factor-1 receptor monoclonal antibody, in combination with cetuximab and irinotecan in Japanese patients with advanced colorectal cancer
Toshihiko Doi, Kei Muro, Takayuki Yoshino, Nozomu Fuse, Takashi Ura, Daisuke Takahari, Hwa-ping Feng, Takashi Shimamoto, Kazuo Noguchi, Atsushi Ohtsu
Phase II study of ifosfamide and cisplatin for the treatment of recurrent ovarian cancer
Taejong Song, Min Kyu Kim, Yoo-Young Lee, Chel Hun Choi, Tae-Joong Kim, Jeong-Won Lee, Byoung-Gie Kim, Duk Soo Bae
Vorinostat in combination with bortezomib in patients with advanced malignancies directly alters transcription of target genes
Jill M. Kolesar, Anne M. Traynor, Kyle D. Holen, Tien Hoang, Songwon Seo, KyungMann Kim, Dona Alberti, Igor Espinoza-Delgado, John J. Wright, George Wilding, Howard H. Bailey, William R. Schelman
The association between the expression of solute carrier transporters and the prognosis of pancreatic cancer
Beatrice Mohelnikova-Duchonova, Veronika Brynychova, Viktor Hlavac, Matej Kocik, Martin Oliverius, Jan Hlavsa, Eva Honsova, Jan Mazanec, Zdenek Kala, Bohuslav Melichar, Pavel Soucek
Molecular and cytogenetic changes in multi-drug resistant cancer cells and their influence on new compounds testing
Ana Podolski-Renić, Milka Jadranin, Tijana Stanković, Jasna Banković, Sonja Stojković, Maria Chiourea, Ivana Aljančić, Vlatka Vajs, Vele Tešević, Sabera Ruždijić, Sarantis Gagos, Nikola Tanić, Milica Pešić
Effects of β-lapachone, a new anticancer candidate, on cytochrome P450-mediated drug metabolism
In Sook Kim, Yun Kim, Tae Hwan Kwak, Hye Hyun Yoo
The small-molecule TNF-α inhibitor, UTL-5g, delays deaths and increases survival rates for mice treated with high doses of cisplatin
Jiajiu Shaw, Joseph Media, Ben Chen, Fredrick Valeriote
Short communication: bendamustine-related hemolytic anemia in chronic lymphocytic leukemia
Neta Goldschmidt, Alexander Gural, Dina Ben-Yehuda, Moshe E. Gatt